Skip to main content
main-content

01.12.2017 | Study protocol | Ausgabe 1/2017 Open Access

Trials 1/2017

ForgIng New paths in DIabetes PrevenTion (FINDIT): Study Protocol for a Randomized Controlled Trial

Zeitschrift:
Trials > Ausgabe 1/2017
Autoren:
Jeffrey T. Kullgren, Bradley Youles, Shaina Shetty, Caroline Richardson, Angela Fagerlin, Michele Heisler
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13063-017-1887-6) contains supplementary material, which is available to authorized users.

Abstract

Background

Prediabetes is an asymptomatic condition in which patients’ blood glucose levels are higher than normal but do not meet diagnostic criteria for type 2 diabetes mellitus (T2DM). A key window of opportunity to increase engagement of patients with prediabetes in strategies to prevent T2DM is when they are screened for T2DM and found to have prediabetes, yet the effects of this screening and brief counseling are unknown.

Methods

In this parallel-design randomized controlled trial we will recruit 315 non-diabetic patients from the Ann Arbor VA Medical Center (AAVA) who have one or major risk factors for T2DM and an upcoming primary care appointment at the AAVA, but have not had a hemoglobin A1c (HbA1c) test to screen for T2DM in the previous 12 months. After informed consent, participants will complete a baseline survey and be randomly assigned to, at the time of their next primary care appointment, one of two arms: (1) to have a hemoglobin A1c (HbA1c) test to screen for T2DM and receive brief, standardized counseling about these results or (2) to review a brochure about clinical preventive services. Participants will complete surveys 2 weeks, 3 months, and 12 months after their primary care appointment, and a weight measurement 12 months after their primary care appointment. The primary outcome is weight change after 12 months. The secondary outcomes are changes in perception of risk for T2DM; knowledge of T2DM prevention; self-efficacy and motivation to prevent T2DM; use of pharmacotherapy for T2DM prevention; physical activity; participation in weight management programs; and mental health. Quantitative analyses will compare outcomes among participants in the HbA1c test arm found to have prediabetes with participants in the brochure arm. Among participants in the HbA1c test arm found to have prediabetes we will conduct semi-structured interviews about their understanding of and reactions to receiving a prediabetes diagnosis.

Discussion

This trial will generate foundational data on the effects of a prediabetes diagnosis and brief counseling on patients’ preventive behaviors and mediators of these behaviors that will enable the development of novel strategies to improve patient engagement in T2DM prevention.

Trial registration

ClinicalTrials.gov, NCT02747108. Registered on 18 April 2016.
Zusatzmaterial
Additional file 1: Standardized brief phone counseling. (DOCX 65 kb)
13063_2017_1887_MOESM1_ESM.docx
Additional file 2: Mailed information about HbA1c results. (DOCX 16 kb)
13063_2017_1887_MOESM2_ESM.docx
Additional file 3: SPIRIT checklist. (DOC 113 kb)
13063_2017_1887_MOESM3_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Trials 1/2017 Zur Ausgabe